EP2661270A1 - Formes posologiques solubles dans l'eau comportant de l'ibandronate - Google Patents

Formes posologiques solubles dans l'eau comportant de l'ibandronate

Info

Publication number
EP2661270A1
EP2661270A1 EP12704937.7A EP12704937A EP2661270A1 EP 2661270 A1 EP2661270 A1 EP 2661270A1 EP 12704937 A EP12704937 A EP 12704937A EP 2661270 A1 EP2661270 A1 EP 2661270A1
Authority
EP
European Patent Office
Prior art keywords
formulation
comprised
formulation according
sodium
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12704937.7A
Other languages
German (de)
English (en)
Inventor
Mahmut Bilgic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP2661270A1 publication Critical patent/EP2661270A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Definitions

  • the present invention discloses water soluble dosage forms comprising ibandronate and/or any pharmaceutically suitable derivative thereof which are developed to be used in prevention and treatment of bone loss and diseases associated with bone loss.
  • Bone loss or in other words "osteoporosis” is defined as a disease characterized by low bone mass and susceptibility to bone fragility as a result of distortion in microstructure of bone tissue and increased risk in bone fracture. The disease does not generally result in death; however, it appears as a major health problem affecting quality of life in the world.
  • Bisphosphonates are pharmaceutical agents which are commonly used in prevention and treatment of bone loss and diseases associated with bone loss. The studies conducted have shown that starting bisphosphonate treatment reduces risk of bone fracture when there appears osteoporosis or nontraumatic bone fracture in postmenopausal period (Fink HA the Fracture Intervention Trial (FIT) 2003).
  • Ibandronate which is a bisphosphonate having the chemical name of l-hydroxy-3-N-methyl- N-pentyl aminopropy 1-1.1- diphosphonic acid was firstly disclosed in the patent numbered DE3623397. It is known that ibandronate is used in treatment of bone diseases, calcium metabolism disorders, osteoporosis, tumor osteolysis or Paget' s disease. Ibandronate should be administered frequently, intermittently and for a long period of time in treatment of said diseases; therefore, the aim of ibandronate administration should be oral administration which is much more accepted by lots of patients in addition to intravenous administration.
  • Ibandronate formulations marketed today are in the form of oral formulations (tablet) and solutions for intravenous injection or infusion which have been improved in accordance with this requirement.
  • the first characteristic feature of the formulation of the present invention is that the formulation is formulated as water soluble dosage forms.
  • the inventors have surprisingly found that water soluble dosage forms comprising ibandronate have higher bioavailability as compared to existing oral formulations and overcome gastrointestinal irritations and said difficulties of use observed in oral formulations.
  • the formulation of the present invention is more advantageous as compared to formulations which are administered intravenously since the patient can use the drug easily by oneself without need of any medical practitioner and this method is painless.
  • the present invention relates to water soluble dosage forms comprising ibandronate and/or a pharmaceutical derivative thereof.
  • Ibandronate comprised in the formulation of the present invention is in the form of its pharmaceutically acceptable hydrates, solvates, esters, enantiomers, polymorphs, crystalline forms, amorphous forms, salts or free base form and/or a combination thereof.
  • Ibandronate comprised in the formulation of the present invention is preferably in salt form.
  • These salts can be selected from organic acid salts such as hydrochloride, hydrobromide, sulphate, phosphate, formate, acetate, trifluoroacetate, methanesulphonate, benzenesulphonate, toluenesulfonate; alkaline metal salts such as sodium, potassium; alkaline earth salts such as calcium, magnesium; organic amine salts such as trimethylamine, triethylamine, pyridine, picoline, dicyclohexylamine or a combination thereof.
  • Ibandronate comprised in the formulation of the present invention is in sodium salt form.
  • Ibandronate comprised in the formulation of the present invention is preferably in hydrate form.
  • hydrates can be selected from hydrates such as anhydrate, monohydrate, dihydrate, trihydrate, hemihydrate, 1 ⁇ 4 hydrate, 1 ⁇ 2 hydrate, 3 ⁇ 4 hydrate, 3 ⁇ 4 hydrate, 5 / 4 hydrate, hydrate, 5 / 2 hydrate and V 2 hydrate.
  • Ibandronate comprised in the effervescent formulation of the present invention is preferably in monohydrate or anhydrate form.
  • the amount of ibandronate comprised in the formulation of the present invention is in the range of 1-1000 mg, preferably in the range of 10-500 mg, more preferably in the range of 25- 250 mg.
  • Ibandronate comprised in the formulation of the present invention is in the range of 1-60 % by weight, preferably in the range of 5-40 % by weight.
  • the water soluble formulation of the present invention is in the form of powder, granule, pellet, micro tablet or tablet.
  • the inventors have encountered effective dissolution and dissolution time problems in the present formulation which are usually encountered in water soluble formulations.
  • the inventors have seen that the rate of pH agent used in the formulation has importance for effective dissolution and dissolution time.
  • pH agent used in the range of 5-40% provides effective dissolution and dissolution time.
  • the formulation of the present invention comprising pH agent in the range of 5-40% forms a homogeneous mixture by dissolving in water in less than 60 seconds.
  • pH agent used in the formulation of the present invention is sodium hydrogen carbonate.
  • the formulation of the present invention can optionally comprise one or more of the following excipients: effervescent couple, binder, lubricant, glidant, diluent, disintegrant, filling agent, flavouring agent, sweetener, colouring agent, surfactant, antifoaming agent, viscosity agent, stabilizing agent.
  • excipients effervescent couple, binder, lubricant, glidant, diluent, disintegrant, filling agent, flavouring agent, sweetener, colouring agent, surfactant, antifoaming agent, viscosity agent, stabilizing agent.
  • excipients effervescent couple, binder, lubricant, glidant, diluent, disintegrant, filling agent, flavouring agent, sweetener, colouring agent, surfactant, antifoaming agent, viscosity agent, stabilizing agent.
  • ' 'effervescent couple' ' refers to use of an
  • the effervescent couple comprised in the effervescent formulation of the present invention is in the range of 0-80% by weight.
  • the acidic agent mentioned herein can be selected from a group composed of acetic acid, citric acid, lactic acid, malic acid, phosphoric acid, propionic acid, tartaric acid or a combination thereof.
  • the basic agent mentioned herein can be selected from a group composed of potassium carbonate, potassium bicarbonate, potassium citrate, potassium hydroxide, sodium carbonate, sodium hydrogen carbonate, sodium hydrogen citrate or a combination thereof.
  • the binder mentioned herein can be selected from starches such as potato starch, corn starch, wheat starch; sugars such as sucrose, glucose, dextrose, lactose, maltodextrin; natural and synthetic gums; gelatin; cellulose derivatives such as microcrystalline cellulose, HPC, HEC, HPMC, carboxymethylcellulose, methylcellulose, ethylcellulose; polyvinylpyrrolidone (povidone); polyethylene glycol (PEG); waxes; calcium carbonate; calcium phosphate; alcohols such as sorbitol, xylitol, mannitol and water or a combination thereof.
  • the lubricant mentioned herein can be selected from sodium lauryl sulphate, sodium benzoate, sodium chloride, sodium acetate, sodium fumarate, carbowax 4000, L-leucine(17), PEG or a combination thereof.
  • the glidant mentioned herein can be selected from talc, magnesium stearate, stearic acid, sodium stearyl fumarate, polyoxyethylene glycol, leucine, alanine, glycine, sodium benzoate, sodium acetate, fumaric acid or a combination thereof.
  • the diluent mentioned herein can be selected from lactose, maltose, dextrin, maltodextrin, mannitol, sorbitol, starch or a combination thereof.
  • the disintegrant mentioned herein can be selected from starches such as potato starch, corn starch, wheat starch, pregelatinized starch, sodium starch glycolate; cellulose derivatives such as croscarmellose sodium or microcrystalline cellulose; polyvinylpyrrolidone; crospovidone; alginic acid and its salts; chyles such as xanthan gum and veegum; ion exchange resins or a combination thereof.
  • the filling agent mentioned herein can be selected from sorbitol, lactose, mannitol or other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulphate, ethyl cellulose, polyacrylates, calcium hydrogen phosphate, sodium hydrogen phosphate, citric acid or a combination thereof.
  • the amount of filling agent used in the formulation of the present invention is in the range of 10-80% by weight, preferably in the range of 40-60% by weight.
  • the filling agent used in the formulation of the present invention is preferably mannitol.
  • the flavouring agent mentioned herein can be selected from natural aroma oils (such as peppermint oil, oil of wintergreen, clove bud oil, parsley oil, eucalyptus oil, lemon oil, orange oil), menthol, menthane, anethole, methyl salicylate, eucalyptol, cinnamon, 1- methyl acetate, sage, eugenol, oxanon, alpha-irisone, marjoram, lemon, orange, blackberry, propenyl guaetol acetyl, cinnamon, vanilla, timole, linalol, cinnamaldehyde glycerol acetal, N-substituted p- menthane-3-carboxamide, 3,1-methoxy propane 1.2-diol or a combination thereof.
  • natural aroma oils such as peppermint oil, oil of wintergreen, clove bud oil, parsley oil, eucalyptus oil, lemon oil, orange oil
  • the sweetener mentioned herein can be selected from sucralose, sucrose, fructose, glucose, galactose, xylose, dextrose, laevulose, lactose, maltose, maltodextrine, mannitol, maltitol, maltol, sorbitol, xylitol, erythritol, lactitol, isomalt, corn syrup, saccharine, saccharine salts, acesulphame potassium, aspartame, D-tryptophan, monoammonium glycyrrhizinate, neohesperidin dihydrochalcone, thaumatin, neotame, alitame, stevioside and cyclamates or a combination thereof.
  • the colouring agent mentioned herein can be selected from carotenoids and chlorophyll or a combination thereof.
  • the surfactant mentioned herein can be selected from sodium lauryl sulphate and magnesium lauryl sulphate or a combination thereof.
  • the antifoaming agent mentioned herein can be selected from simethicone emulsion and dimethyl siloxane, silicone oil or a combination thereof.
  • the viscosity agent mentioned herein can be selected from carboxymethyl cellulose, methyl cellulose, xanthan gum, gummi tragacanthae, gum arabic, aerosil 200, colloidon, agar-agar, bentonite, hydroxyethyl cellulose or a combination thereof.
  • the stabilizing agent and/or agents mentioned herein can be selected from antioxidants, chelating agents, alkalinizing agents and photo protective agents.
  • the antioxidants can be selected from substances such as butylated hydroxyanisole (BHA), sodium ascorbate, butylated hydroxytoluene (BHT), sodium sulphite, gallates (such as propyl gallate), tocopherol, citric acid, malic acid, ascorbic acid, acetylcysteine, fumaric acid, lecithin, ascorbyl palmitate, ethylenediamine tetraacetate or a combination thereof.
  • BHA butylated hydroxyanisole
  • BHT butylated hydroxytoluene
  • gallates such as propyl gallate
  • tocopherol citric acid, malic acid, ascorbic acid, acetylcysteine, fumaric acid, lecithin, ascorbyl palmitate, ethylenediamine tetraacetate or a combination thereof.
  • the chelating agents can be selected from disodium EDTA, edetic acid, citric acid, sodium citrate, potassium citrate or a combination thereof.
  • the alkalizing agents can be selected from alkali metal salts such as sodium carbonate, sodium hydrogen carbonate, sodium hydroxide, sodium silicate, disodium hydrogen ortophosphate, sodium aluminate; earth alkali metal salts such as calcium carbonate, calcium hydroxide, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulphate, calcium acetate, calcium gluconate, calcium glycerophosphate, magnesium carbonate, magnesium hydroxide, magnesium sulphate, magnesium acetate, magnesium silicate, magnesium aluminate and organic compounds such as primary, secondary and tertiary amines, cyclic amines, N-N'-dibenzylethylenediamine, diethanolamine, ethylenediamine, meglumine, monosodium glutamate, polyacryline sodium, sodium alginate or a combination thereof.
  • alkali metal salts such as sodium carbonate, sodium hydrogen carbonate, sodium hydroxide, sodium silicate, disodium hydrogen ortophosphate
  • the photoprotective agents can be selected from metal oxides such as titanium oxide, iron oxide or zinc oxide or a combination thereof.
  • the formulation of the present invention comprises
  • the formulation of the present invention can be used in treatment of osteoporosis; in order to reduce risk of bone fracture in women including spine bone and hipbone; in order to reduce risk of bone fracture in men; in treatment of diseases such as idiopathic osteoporosis; osteoporosis induced by various diseases; steroid and glucocorticoid-induced osteoporosis ; osteopenia, osteomalacia, osteogenesis imperfecta, osteochondrodysplasia, sudeck atrophy, rheumatoid arthritis, Paget's disease, bone metastasis of malignant tumors, hypercalcaemia or hyperthyroidism; and particularly in adolescence, pregnant or nursing women in premenopausal and postmenopausal period in order to preserve bone health as nutrition reinforcement.
  • diseases such as idiopathic osteoporosis; osteoporosis induced by various diseases; steroid and glucocorticoid-induced osteoporosis ; osteopenia, osteo
  • Ibandronate sodium, pH agent, the filling agent and the other excipients are mixed in a container.
  • the mixture obtained is loaded into sachet filling machines and sachet filling is performed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention porte sur des formes posologiques solubles dans l'eau qui comportent de l'ibandronate et/ou tout dérivé de qualité pharmaceutique de celui-ci, qui sont développées pour être utilisées dans la prévention et le traitement d'une perte osseuse et de maladies osseuses associées à une perte osseuse.
EP12704937.7A 2011-01-06 2012-01-06 Formes posologiques solubles dans l'eau comportant de l'ibandronate Withdrawn EP2661270A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2011/00151A TR201100151A2 (tr) 2011-01-06 2011-01-06 İbandronate formülasyonu.
PCT/TR2012/000010 WO2012093979A1 (fr) 2011-01-06 2012-01-06 Formes posologiques solubles dans l'eau comportant de l'ibandronate

Publications (1)

Publication Number Publication Date
EP2661270A1 true EP2661270A1 (fr) 2013-11-13

Family

ID=46457629

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12704937.7A Withdrawn EP2661270A1 (fr) 2011-01-06 2012-01-06 Formes posologiques solubles dans l'eau comportant de l'ibandronate

Country Status (3)

Country Link
EP (1) EP2661270A1 (fr)
TR (1) TR201100151A2 (fr)
WO (1) WO2012093979A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104922060B (zh) * 2015-05-23 2017-10-20 河北仁合益康药业有限公司 一种伊班膦酸钠注射液组合物
CN107670103A (zh) * 2017-09-15 2018-02-09 天津大学 聚乙烯吡络烷酮改性的骨水泥及制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3623397A1 (de) 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
EP0939624B1 (fr) * 1996-05-17 2003-12-17 Merck & Co., Inc. Formulation de bisphosphonate efferverscente
US5853759A (en) * 1996-05-17 1998-12-29 Merck & Co.. Inc. Effervescent alendronate formulation
US20060034921A1 (en) * 2004-01-05 2006-02-16 Katdare Ashok V Effervescent bisphosphonate formulation
US20070087052A1 (en) * 2005-10-19 2007-04-19 Katdare Ashok V Effervescent bisphosphonate formulation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2012093979A1 *

Also Published As

Publication number Publication date
TR201100151A2 (tr) 2012-07-23
WO2012093979A1 (fr) 2012-07-12

Similar Documents

Publication Publication Date Title
JP4346817B2 (ja) 経口投与製剤
WO2011152810A1 (fr) Formulations comprenant du calcium, de la vitamine d et de la vitamine k pour traiter l'ostéoporose
JP4619658B2 (ja) 快い味の経口懸濁液および方法
MX2014004811A (es) Composicion farmaceutica de sabor enmascarado para administracion oral, y proceso para la preparacion de la misma.
WO2012002918A1 (fr) Formulation pour l'ostéoporose
EP2393478B1 (fr) Compositions pharmaceutiques à l'odeur et au goût masqués hautement biodisponibles
US9480655B2 (en) Solid pharmaceutical dosage form of dolutegravir
WO2010101537A1 (fr) Composition pharmaceutique de principes actifs combinés en forme posologique unique
WO2012093972A1 (fr) Formes galéniques solubles dans l'eau
EP2661270A1 (fr) Formes posologiques solubles dans l'eau comportant de l'ibandronate
EA036278B1 (ru) Фармацевтическая композиция
WO2013052019A1 (fr) Procédé de fabrication de formulations effervescentes comportant du diclofénac
ES2865289T3 (es) Composiciones farmacéuticas que comprenden 3-(5-amino-2-metil-4-oxo-4H-quinazolin-3-il)-piperidin-2,6-diona
EP2661262B1 (fr) Formulations améliorées de bisphosphonates
WO2011093831A2 (fr) Formulations effervescentes contenant du cefprosil comme principe actif
EP2661258B1 (fr) Formulation améliorée à base de risédronate
EP2661257B1 (fr) Formulations effervescentes de bisphosphonate
US20140030326A1 (en) Effervescent formulations comprising dexketoprofen
JP2018145095A (ja) エルロチニブ塩酸塩含有医薬組成物
EP2566458B1 (fr) Formulations pharmaceutiques comprenant du céfuroxime axétil
WO2012026904A1 (fr) Forme galénique unidose réalisée à partir d'une combinaison comprenant du donépézil et de l'extrait de ginkgo biloba
EP2566450A2 (fr) Compositions pharmaceutiques comprenant du céfétamet
WO2012093971A2 (fr) Compositions effervescentes contenant de l'amlodipine
KR101685710B1 (ko) 해열 진통 조성물
WO2012026903A1 (fr) Compositions synergiques comprenant de la mémantine et de l'extrait de gingko biloba

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130805

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20170131